Azetukalner in Adults With Focal Seizures
Abstract
Key Points Question Does azetukalner, a novel, potent KV7 channel opener, effectively reduce seizure frequency in adults experiencing focal seizures despite established treatment with up to 3 antiseizure medications at baseline? Findings This randomized clinical trial among 374 participants found that treatment with azetukalner resulted in a rapid and durable reduction in seizure frequency and was generally well tolerated. These results are consistent with prior azetukalner results in focal epilepsy. Meaning The results support azetukalner as a promising next-generation antiseizure medication with the potential to advance care for people with epilepsy.